Side-by-side · Research reference

GlutathionevsKisspeptin-10

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED6/39 cited

BPhase 2HUMAN-REVIEWED10/41 cited

Glutathione

Endogenous Tripeptide · Antioxidant

γ-Glu-Cys-GlyStructure

UbiquitousTissue distribution

GCL + GSBiosynthesisWang 2026 Aiana 2026

IV · Oral · Inhaled

Kisspeptin-10

Neuropeptide · GPR54 Agonist

GnRH pulse generatorPrimary roleSilva 2026

Phase 1/2Clinical stage

GPR54/Kiss1RTarget receptorRønnekleiv 2026

IV / SQ · Investigational

01Mechanism of Action

Parameter

Glutathione

Kisspeptin-10

Primary target

Intracellular redox systems, glutathione peroxidase, glutathione transferase

GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026 Collado-Sole 2026

Pathway

Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH

Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026 Rønnekleiv 2026

Downstream effect

Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction

Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026

Feedback intact?

—

Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026 Rønnekleiv 2026

Origin

Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025 Hecht 2026

C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms

Antibody development

—

02Dosage Protocols

Parameter

Glutathione

Kisspeptin-10

Endogenous synthesis

Hepatic synthesis ~10 g/day (basal rate)

Tissue-specific; demand-driven upregulation via Nrf2 signaling.

—

Exogenous oral

250–1000 mg/day

Bioavailability limited; gastric hydrolysis reduces systemic uptake.

—

IV supplementation

600–1200 mg (research protocols)

Used in clinical oxidative stress and hepatic detoxification studies.

—

Precursor strategy

N-acetylcysteine (NAC) 600–1200 mg/day

Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.

—

Evidence basis

Animal mechanistic + human mechanistic

Phase 1/2 trials

Clinical trial dose

—

Phase 1/2 investigational

Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).

Route

—

IV or SQ administration

IV preferred in controlled trials for precise pulsatile delivery.

Half-life

—

Short (minutes)

Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.

04Side Effects & Safety

Parameter

Glutathione

Kisspeptin-10

Oral supplementation

GI discomfort, bloating (mild, dose-dependent)

—

IV administration

Rare hypersensitivity, infusion site reaction

—

Inhalation

Bronchospasm risk in asthma (rare)

—

Tumor metabolism

Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026

—

Ovarian hyperstimulation

—

Theoretical risk with supraphysiological dosing in fertility protocols

Headache

—

Mild, reported in early-phase trials

Nausea

—

Transient GI symptoms with IV bolus

Hot flashes

—

Vasomotor symptoms from LH surge

Injection site reaction

—

Erythema, mild discomfort (SQ route)

Absolute Contraindications

Glutathione

—

Kisspeptin-10

·Active pregnancy
·Hormone-sensitive malignancy (breast, ovarian, endometrial)

Relative Contraindications

Glutathione

·Active malignancy (theoretical cysteine supply risk)Hecht 2026
·Severe asthma (inhaled formulations)

Kisspeptin-10

·Polycystic ovary syndrome (PCOS) without monitoring
·Uncontrolled thyroid dysfunction

05Administration Protocol

Parameter

Glutathione

Kisspeptin-10

1. Oral administration

Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.

Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.

2. Intravenous

Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.

IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.

3. Inhaled formulations

Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.

Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.

4. Precursor supplementation

N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.

Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.

5. Storage

—

Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.